Bafna Pharmaceuticals Ltd vs Oxygenta Pharmaceutical Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: Jun 13, 2026

Key Highlights

The Latest Trading Price of Bafna Pharmaceuticals Ltd is ₹ 166.25 as of 12 Jun 15:30 . The P/E Ratio of Bafna Pharmaceuticals Ltd changed from 55.8 on March 2021 to 42.6 on March 2025 . This represents a CAGR of -5.26% over 5 yearsThe P/E Ratio of Oxygenta Pharmaceutical Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 years The Market Cap of Bafna Pharmaceuticals Ltd changed from ₹ 324.8 crore on March 2021 to ₹ 177.42 crore on March 2025 . This represents a CAGR of -11.39% over 5 yearsThe Market Cap of Oxygenta Pharmaceutical Ltd changed from ₹ 34.15 crore on March 2022 to ₹ 294.24 crore on March 2025 . This represents a CAGR of 71.33% over 4 years The revenue of Bafna Pharmaceuticals Ltd for the Mar '26 is ₹ 44 crore as compare to the Dec '25 revenue of ₹ 39.51 crore. This represent the growth of 11.36% The revenue of Oxygenta Pharmaceutical Ltd for the Mar '26 is ₹ 49.79 crore as compare to the Dec '25 revenue of ₹ 33.93 crore. This represent the growth of 46.74% The ebitda of Bafna Pharmaceuticals Ltd for the Mar '26 is ₹ 5.31 crore as compare to the Dec '25 ebitda of ₹ 4.27 crore. This represent the growth of 24.36% The ebitda of Oxygenta Pharmaceutical Ltd for the Mar '26 is ₹ 0.29 crore as compare to the Dec '25 ebitda of ₹ -4.08 crore. This represent the decline of -107% The net profit of Bafna Pharmaceuticals Ltd changed from ₹ -0.72 crore to ₹ 2.75 crore over 8 quarters. This represents a CAGR of NaN% The net profit of Oxygenta Pharmaceutical Ltd changed from ₹ -1.36 crore to ₹ -1.7 crore over 8 quarters. This represents a CAGR of 11.80% The Dividend Payout of Bafna Pharmaceuticals Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Oxygenta Pharmaceutical Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Bafna Pharmaceuticals Ltd

Bafna Pharmaceuticals Limited (BPL) was started as a proprietary concern in 1981 by Mr. Bafna Mahaveer Chand in the name of Bafna Pharmaceutical and is engaged in the manufacturing of pharmaceutical formulations of Betalactum and Non Betalactum products.
The first manufacturing unit was set up at Madhavaram (Chennai) during October 1984 for manufacture of tablets with an installed capacity of 420 lacs tablets p.a.
Subsequently the capsule line was added during 1987 with a capacity of 300 lacs capsule p.a. and then liquid line with an installed capacity of 45000 lts p.a was added in 1990. Bafna Pharmaceuticals, incorporated in 1995, had acquired the entire business of the proprietary concern.
During the year 2001, the company constructed a separate block at Madhavaram for manufacturing Betalactum products.

About Oxygenta Pharmaceutical Ltd

Oxygenta Pharmaceutical Limited was initially incorporated as S S Organics Private Limited as a private limited Company in 1990.
The Company converted its status to a Public Limited Company in 1993 changing the name to S S Organics Limited.
Further, it was changed to Oxygenta Pharmaceutical Limited in FY 2021-22. The Company was incorporated with the objective of carrying on the business of manufacturing all classes and kinds of Drugs including Pharmaceutical preparation, and Organic Fine Chemicals.
It manufactures a wide range of new generation quinolones, antiasthmatic, antiulcerant, and anti-inflammatory drugs.
The Company has plant located at Medak in Andhra Pradesh. The Company is strong in manufacturing of anti ulcerative and anti bacterial drugs.

FAQs for the comparison of Bafna Pharmaceuticals Ltd and Oxygenta Pharmaceutical Ltd

Which company has a larger market capitalization, Bafna Pharmaceuticals Ltd or Oxygenta Pharmaceutical Ltd?

Market cap of Bafna Pharmaceuticals Ltd is 393 Cr while Market cap of Oxygenta Pharmaceutical Ltd is 179 Cr

What are the key factors driving the stock performance of Bafna Pharmaceuticals Ltd and Oxygenta Pharmaceutical Ltd?

The stock performance of Bafna Pharmaceuticals Ltd and Oxygenta Pharmaceutical Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Bafna Pharmaceuticals Ltd and Oxygenta Pharmaceutical Ltd?

As of June 13, 2026, the Bafna Pharmaceuticals Ltd stock price is INR ₹166.25. On the other hand, Oxygenta Pharmaceutical Ltd stock price is INR ₹48.58.

How do dividend payouts of Bafna Pharmaceuticals Ltd and Oxygenta Pharmaceutical Ltd compare?

To compare the dividend payouts of Bafna Pharmaceuticals Ltd and Oxygenta Pharmaceutical Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.